Provided by Tiger Trade Technology Pte. Ltd.

Immunic, Inc.

1.09
-0.1700-13.49%
Post-market: 1.100.0113+1.04%19:58 EDT
Volume:3.38M
Turnover:3.89M
Market Cap:142.21M
PE:-1.75
High:1.28
Open:1.26
Low:1.09
Close:1.26
52wk High:1.51
52wk Low:0.5062
Shares:130.46M
Float Shares:95.79M
Volume Ratio:1.70
T/O Rate:3.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6241
EPS(LYR):-0.6241
ROE:-1653.15%
ROA:-198.76%
PB:-21.31
PE(LYR):-1.75

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Moderna, Mohawk,

Reuters
·
Feb 14

Why Is Immunic Stock (IMUX) Up 27% Today?

TIPRANKS
·
Feb 13

BUZZ-U.S. STOCKS ON THE MOVE-Opus Genetics, MetaVia, Enbridge

Reuters
·
Feb 13

Immunic Shares Climb After Private Placement Is Priced

Dow Jones
·
Feb 13

Immunic Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Feb 13

Shares of Immunic up 21.8% Premarket After Co Raises $400 Mln for Multiple Sclerosis Drug Trials

THOMSON REUTERS
·
Feb 13

BUZZ-Immunic jumps as biotech raises up to $400 million for MS drug trials

Reuters
·
Feb 13

Immunic Announces Oversubscribed Private Placement Of Up To USD 400 Million To Accelerate Transformation Into Commercial-Stage Company

Reuters
·
Feb 13

Immunic Announces Issuance of Warrants to Raise Up to $200 Million

Reuters
·
Feb 13

Eqs-News: Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation Into Commercial-Stage Company

THOMSON REUTERS
·
Feb 13

Immunic Inc - Co-Founder and Chief Executive Officer Daniel Vitt and Board of Directors Will Begin a Search for a New CEO

THOMSON REUTERS
·
Feb 13

Immunic Inc: Proceeds of Financing Expected to Support Co's Transition From Research & Development-Focused Co Into Fully Integrated Commercial Entity

THOMSON REUTERS
·
Feb 13

Press Release: Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

Dow Jones
·
Feb 13

Immunic Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 09

Immunic Unveils Positive Phase 2 CALLIPER Trial Data for Vidofludimus Calcium in Progressive Multiple Sclerosis

Reuters
·
Feb 04

Eqs-News: Immunic to Present Additional Phase 2 Calliper Trial Data for Vidofludimus Calcium at the Actrims Forum 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

THOMSON REUTERS
·
Feb 04

Insider Traders Lose US$42k As Immunic Drops

Simply Wall St.
·
Jan 30

Immunic Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 07

Immunic Inc. Faces Nasdaq Delisting Risk Over Continued Low Share Price

Reuters
·
Jan 07

Immunic Inc. Sets New CEO Pay Package for Duane Nash

Reuters
·
Jan 06